Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...
Calcipotriol plus 5-FU immunotherapy activates Th2 immunity, releasing IL-24 cytokines to suppress skin cancer development in patients with actinic keratosis. The combination therapy significantly ...
Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4). Biologics targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback